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Abstract
Purpose
To evaluate an EW-7197-eluting nanofiber-covered stent (NFCS) for suppressing granula-
tion tissue formation after stent placement in a canine urethral model.
Materials and methods
All experiments were approved by the committee of animal research. A total of 12 NFCSs
were placed in the proximal and distal urethras of six dogs. Dogs were divided into two
groups with 3 dogs each. The control stent (CS) group received NFCSs and the drug stent
(DS) group received EW-7197 (1000 μg)-eluting NFCSs. All dogs were sacrificed 8 weeks
after stent placement Histologic findings of the stented urethra were compared using the
Mann-Whitney U test.
Results
Stent placement was technically successful in all dogs without procedure-related complica-
tions. On urethrographic analysis, the mean luminal diameter was significantly larger in the
DS group than in the CS group at 4 and 8 weeks after stent placement (all p < 0.001). On his-
tological examination, mean thicknesses of the papillary projection, thickness of submuco-
sal fibrosis, number of epithelial layers, and degree of collagen deposition were significantly
lower in the DS group than in the CS group (all p < 0.001), whereas the mean degree of
inflammatory cell infiltration was not significantly different (p > 0.05).
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Conclusion
The EW-7197-eluting NFCS is effective and safe for suppressing granulation tissue forma-
tion after stent placement in a canine urethral model.
Introduction
Placement of a covered self-expandable stent (SEMS) is a well-established method for the treat-
ment of luminal strictures involving various nonvascular organs [1–5]. However, these stents
exert constant mechanical stress to the adjacent tissue, resulting in granulation tissue forma-
tion. This is a major drawback of stent placement because granulation tissue formation can
cause restenosis and recurrence of symptoms. Stent placement in the urethra is not an excep-
tion; therefore, granulation tissue formation is widely recognized as one of the most important
obstacles to long-term stent placement in the urethra [5–8].
There is a growing understanding of the molecular mechanism of granulation tissue forma-
tion, and transforming growth factor-β1 (TGF-β1) has emerged as a key component in the
proliferation of granulation tissue [9,10]. The desire to block the TGF-β1 signaling pathway
has led to the development of several small-molecule drugs that act by inhibiting TGF-β1 from
binding to its receptors [11,12]. Of these, EW-7197 is a novel oral TGF-β type-1 receptor
kinase inhibitor [13,14]. This drug has been shown to have strong antifibrotic properties in
animals [15,16] and the development of a drug-eluting stent using EW-7197 may be an attrac-
tive alternative for suppressing granulation tissue formation after stent placement in the ure-
thra. Nanofiber meshes are flexible and highly porous meshes that is suitable for coating
metallic stents and providing local drug delivery [17]. Recently, we have developed an EW-
7197-eluting nanofiber-covered stent (NFCS). We hypothesized that this stent would suppress
granulation tissue formation after stent placement in the urethra. Therefore, the purpose of
this study was to evaluate EW-7197-eluting NFCSs for suppressing granulation tissue forma-
tion after stent placement in a canine urethral model.
Materials and methods
EW-7197-eluting nanofiber-covered stent
Stent construction. The stent used in this study was woven six times into a tubular con-
figuration with six bends from a single thread of 0.15-mm-thick nitinol wire filament (Fig 1A).
When fully expanded, the stent had a diameter of 10 mm and a length of 20 mm. Two radi-
opaque markers were attached to the ends of the stent to facilitate stent placement. The stent
was made to our specifications by a local manufacturer (S&G biotech, Seongnam, Korea).
EW-7197-eluting nanofiber coating over the stent. The nanofiber covering membrane
[drug-eluting poly-DL-lactic acid (PDLLA) and polyurethane (PU) backing layers] used in this
study was constructed using electrospinning techniques. The electrospun scaffolds were con-
structed on the surface of the rolling stent and vacuum dried at room temperature for 24 h. PU
(10 w/v%) and solvent polymer (90 w/v%) as a core was dissolved in tetrahydrofuran/dimethyla-
cetamide (2:1) solution and then electrospun from the syringe at a rate of 0.2 ml/h. PDLLA (3.3
w/v%) and EW 7197 (20 w/v%) as a shell was sprayed from the syringe at a rate of 0.73 ml/h at the
same time. The stents were rotated at 300 rpm and increased to 500 rpm over 2–4 h. Each EW-
7197-eluting NFCS contained 1000 μg of EW-7197. A nanofiber layer on the surface of the stent
was examined with a scanning electron microscope (SEM; TM-1000; Hitachi, Krefeld, Germany).
The electrospun layer exhibited an apparent nanofiber structure, as shown in Fig 1B.
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In vitro release study of EW-7197 nanofiber membrane. EW-7197 nanofiber membrane
was placed inside a 50-mL conical tube with 50 mL of release medium, 10-mM PBS buffer of
pH of 7.4 (n = 6). The tubes were placed in a shaking incubator at 37˚C and 50 rpm. The
release medium in each tube was collected at the predetermined time for further analysis,
replaced with fresh media, and the concentration of EW-7197 was determined using a (high
performance liquid chromatography) HPLC system (Agilent 1200 series, USA). The HPLC
analysis was performed as follows. The composition of mobile phase was 71% water and 29%
acetonitrile with 0.1% trifluroacetic acid. The flow rate was 1 mL/min throughout the 10-min
run at 40˚C. Chromatography was performed at 40˚C and the eluent was monitored at a wave-
length of 260 nm.
Animal study. The Institutional Animal Care and Use Committee at Asan medical center
approved this study, which was conducted in accordance with the United States National Insti-
tutes of Health Guidelines on Humane Care and Use of Laboratory Animals.
Six male mongrel dogs (weight range, 20–25 kg; Orient Bio, Seongnam, Korea) were used
for this study. A total of 12 NFCSs were placed in the proximal and distal urethras of six dogs.
Fig 1. Representative optical images of (A) Nanofiber-covered, self-expandable metallic stent and (B) scanning electron
micrographs of EW-7197 loaded nanofibers. The scale bars are 30 μm and 10 μm.
https://doi.org/10.1371/journal.pone.0192430.g001
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Dogs were divided into two groups with 3 dogs each. The dogs in the control stent (CS) group
received non-drug eluting NFCSs in the proximal and distal urethras and the dogs in the drug
stent (DS) group received EW-7197 (1000 μg)-eluting NFCSs in the proximal and distal ure-
thras. All dogs were maintained in an independent cage (width: 1150 mm, depth: 1430 mm,
and height: 2210 mm) made of stainless steel and they were allowed to socialize with animal
care staff when the cage was cleaned twice a day. All dogs were supplied with food and water
and mean room temperature was kept at 24˚C with a 12-hour day-night schedule, which was
fully automatically controlled. After stent placement, daily diet consumption, weight change,
and behavioral change were monitored on a weekly basis. At 8 weeks after stent placement,
dogs were sacrificed for histologic analysis. None of the dogs died prior to the study endpoints.
Stent placement. General anesthesia was induced by intra-muscularly administered keta-
mine hydrochloride (Yuhan, Seoul, Korea) and atropine sulfate (Daewon, Seoul, Korea) and
was maintained with intravenously administered ketamine hydrochloride. After disinfecting
the external urethral orifice with 0.05% chlorhexidine (Daewoong, Seoul, Korea), the urethra
was lubricated using 2% lidocaine jelly (Dongsan, Ansan, Korea). A 180-cm guide wire (Radio-
focus M; Terumo, Tokyo, Japan) was then inserted through the urethra and advanced into the
urinary bladder. Retrograde urethrography (RGU; Omnipaque 300; GE Healthcare, Cork, Ire-
land) was performed using a straight 5F graduated catheter (Cook, Bloomington, Indiana) to
determine the location of stent placement. Under fluoroscopic guidance (Artis Zee Multipur-
pose; Siemens, Muenchen, Germany), a stent-delivery system, consisting of a 10F sheath, a
guiding olive tip, and a pusher catheter, was passed over the guide wire and advanced to the
middle portion of the proximal urethra. The pusher catheter was then held in place with one
hand while the sheath was slowly withdrawn in a continuous motion with the other hand until
the NFCS was deployed. The stent-delivery system was then removed with the guide wire left
in place, and another NFCS was placed in the middle portion of the distal urethra using the
same technique. Antibiotics (penicillin, 800,000 U/day) and analgesics (ketoprofen, 1 ml/5 kg)
were used for a period of three days after stent placement.
Urethrographic examination. In all dogs, RGU was performed in right anterior oblique
projections with use of a straight 5F graduated catheter (Cook, Bloomington, Indiana) imme-
diately after stent placement to verify position and patency of the stent. Follow-up RGU was
performed 4 and 8 weeks later, and the luminal diameter was measured with the use of cali-
brated catheter. Software (Photoshop, version 6.0; Adobe Systems, Palo Alto, Calif) was used
to acquire digital measurements of the inner luminal diameter of the stented urethra at three
different levels. Measurements were repeated three times at each level, yielding an average
value per level, and these values were subsequently averaged to obtain an overall average diam-
eter of the segment. Analyses of the urethrographic findings were performed on the basis of
the consensus of three observers blinded to the study.
Histological examination. All dogs were sacrificed by means of administration of an
overdose of xylazine hydrochloride (Rompun; Bayer, Seoul, Korea) 8 weeks after stent place-
ment. The urethral tissue samples were fixed in 10% neutral-buffered formalin for 24 h. Fixed
tissue samples were longitudinally sectioned at the three different portions of the segment with
the stent (Fig 2). Paraffin blocks were prepared from the tissue samples and 5-μm-thick sec-
tions were obtained with a MR2258 microtome (HostoLine, Pantigliate, Italy). The slides were
stained with hematoxylin and eosin (H&E) and Masson’s trichrome (MT) stains. Histological
examination after H&E staining included determining the degree of submucosal inflammatory
cell infiltration, the number of epithelial layers, the thickness of submucosal fibrosis, and the
thickness of papillary projection. The degree of inflammatory cell infiltration was subjectively
determined according to the distribution and density of the inflammatory cells (graded as 1,
mild; 2, mild to moderate; 3, moderate; 4, moderate to severe; and 5, severe). The average
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values for the degree of inflammatory cell infiltration, the number of epithelial layers, the
thickness of submucosal fibrosis, and the thickness of papillary projection were obtained by
averaging eight points [18–20]. The degree of collagen deposition was determined on MT
stained sections. Degree of collagen deposition was subjectively determined where 1 = mild,
2 = mild to moderate, 3 = moderate, 4 = moderate to severe, and 5 = severe. Histological exam-
ination of the urethra was performed with a BX51 microscope (Olympus, Tokyo, Japan). Mea-
surements were obtained using Image-Pro Plus software (Media Cybernetics, Silver Spring,
MD, USA). Analyses of the histological findings were performed on the basis of the consensus
of three observers blinded to the study.
Statistical analysis. Data are expressed as the mean ± standard deviation. Comparisons
between two groups were performed using the Mann–Whitney test. A p value of<0.05 indi-
cates statistical significance. Statistical analyses were performed using SPSS software (version
22.0; SPSS, IBM, Chicago, IL, USA).
Results
In vitro release study
To evaluate the drug release behavior of the PU (core)—PLLLA (shell) stents, in vitro drug
release was monitored for 60 days using an HPLC system. As shown in Fig 3, approximately
Fig 2. Locations of tissue sampled for histological examination. The canine urethra consists of the proximal pelvic urethra (arrows)
and the distal cavernous urethra (arrowheads). (A) Retrograde urethrography of the canine urethra immediately after stent placement.
(B) Schematic image showing the locations of tissue samples where a stent was present.
https://doi.org/10.1371/journal.pone.0192430.g002
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80% of the encapsulated EW-7197 was released from the stents within 1 day, and the remain-
ing encapsulated EW-7197 was slowly released thereafter.
Stent placement
Stent placement was technically successful in all dogs without complications. A small amount
of hematuria occurred immediately after stent placement in all dogs, but it subsided spontane-
ously. All animals survived until the end of the study without stent-related complications.
Urethrographic findings
The urethrographic findings are summarized in Table 1 and are presented in Fig 4. At 4 weeks,
the luminal diameter of the proximal stented urethra in the DS group was significantly larger than
the CS group (p< 0.001). There was also a significant difference between the DS and CS groups
(p = 0.002) in the luminal diameter of the distal stented urethra. The overall luminal diameter of
the stented urethra in the DS group was significantly larger than the CS group (p< 0.001). At 8
weeks, the luminal diameter of the stented urethra in the DS group was significantly larger than
the CS group for both the proximal (p< 0.001) and distal urethras (p = 0.015).
Histological findings
The histological findings are presented in Table 2, and examples are shown in Fig 5. The over-
all mean thickness of the papillary projection was significantly less in the DS group than in the
Fig 3. Curves show in vitro release profiles of EW-7197 from nanofiber membrane at (A) 5 days and (B) 60 days. Error bars = standard
deviation of mean (n = 6).
https://doi.org/10.1371/journal.pone.0192430.g003
Table 1. Retrograde urethrographic findings after stent placement in canine urethra.
Location 4 weeks follow-up p value 8 weeks follow-up p value
CS group DS group CS group DS group
Proximal 7.36 ± 1.51 9.20 ± 1.74 <0.001 6.68 ± 1.39 8.60 ± 1.37 <0.001
Distal 6.62 ± 1.32 8.31 ± 1.57 0.002 6.20 ± 1.05 7.72 ± 1.58 0.015
Total 6.99 ± 1.45 8.67 ± 1.66 <0.001 6.51 ± 1.27 8.16 ± 1.46 <0.001
Note. Data are mean diameters of the six stented urethra in millimeters ± standard deviations. CS; control stent, DS; drug stent
https://doi.org/10.1371/journal.pone.0192430.t001
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CS group for both the proximal and distal stented urethra (all p< 0.001). The mean thickness
of submucosal fibrosis (all p< 0.001) and the mean number of epithelial layers (all p< 0.001)
were also significantly less in the DS group than in the CS group for both the proximal and dis-
tal stented urethra. The mean degree of inflammatory cell infiltration did not significantly dif-
fer between the CS and DS groups (p = 0.480; proximal urethra, p = 0.484; distal urethra,
p = 0.742). The mean degree of collagen deposition was significantly less in the DS group than
in the CS group for both the proximal and distal urethras (all p< 0.001). The comparison
between the proximal and distal urethras did not show significant differences for any variables
between groups (all p> 0.05).
Discussion
Placement of SEMSs for benign and malignant strictures of various organs has been around
for several decades [1–5]. The downside of this treatment is restenosis resulting from granula-
tion tissue formation through the mesh or around the edges of the stents [21]. Deeper under-
standings into the pathophysiology of granulation tissue formation and advances in stent
Fig 4. Retrograde urethrography images obtained 8 weeks after stent placement in dogs. (A) Image obtained after
control stent placement shows filling defects (arrowheads) at both ends of the stents and in-stent stenosis (arrows)
resulting from granulation tissue formation. (B) Image in drug stent group shows mild in-stent restenosis (arrows) in
the proximal and distal stented urethras (arrows). At both ends of the stents, no definite filling defects were seen.
https://doi.org/10.1371/journal.pone.0192430.g004
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technology have expanded their clinical applications. There have been several efforts to use
drug-eluting stents in the treatment of strictures in nonvascular luminal organs [22–24]. The
benefits of stent-based drug delivery are to maximize the level of therapeutic agents in local tis-
sue, lower drug dosage, and minimize systemic toxicity. In the present study, we designed
EW-7197-eluting covered stents and tested their efficacy in suppressing granulation tissue
formation in an animal model. Our results suggest that EW-7197 locally delivered by a stent
successfully reduces or inhibits granulation tissue formation secondary to stent-induced
mechanical injury in a canine urethral model, as evidenced by significantly larger luminal
diameter on RGU and less granulation tissue formation on histological examination in the DS
group than in the CS group.
TGF-β and its receptors are uniformly overexpressed in fibrotic diseases of various organs,
and it has been reported to be a potent, profibrogenic cytokine resulting in pathologic fibrosis
[9,25]. Therefore, the signaling pathway for fibrosis via TGF-β has been a promising target for
drug development. Various attempts to block the TGF-β pathway have been made and EW-
7197 is a recently introduced TGF-β type-1 receptor kinase inhibitor [13]. The safety and effi-
cacy of EW-7197 has been documented in animal models, and several investigators have
reported that EW-7197 safely inhibited hepatic, renal, and pulmonary fibrosis and stent-
induced granulation tissue formation by blocking the TGF-β/Smad and/or reactive oxygen
species (ROS) signaling pathway [15,16,26]. As stent-induced benign stricture appeared to be
subject to TGF-β, EW-7197 was used as an antifibrotic agent in the present study.
In the current study, granulation tissue formation based on the luminal diameter of the
stented urethra and histological examination was significantly decreased in the DS group com-
pared to the CS group in both the proximal and distal urethras. In a study by Shin et al., they
placed the paclitaxel-eluting covered stents into canine urethras and reported that decreased
granulation tissue formation was observed only in the proximal urethra [20]. They postulated
that the distal urethra, with a smaller diameter, was less expandable and exposed to higher
mechanical microtrauma than in the proximal urethra. As a result, granulation tissue forma-
tion was thought to be more prominent in the distal urethra. Despite the different anatomic
Table 2. Histological findings after stent placement in canine urethra.
Location CS group DS group p value
Thickness of Papillary Projection (mm) Proximal 2.67 ± 0.48 1.11 ± 0.28 <0.001
Distal 2.78 ± 0.56 1.26 ± 0.35 <0.001
Total 2.72 ± 0.52 1.19 ± 0.31 <0.001
Thickness of Submucosal Fibrosis (mm) Proximal 1.27 ± 0.55 0.67 ± 0.11 <0.001
Distal 1.33 ± 0.64 0.64 ± 0.12 <0.001
Total 1.30 ± 0.58 0.66 ± 0.11 <0.001
Number of Epithelial Layers Proximal 4.84 ± 0.76 3.56 ± 0.72 <0.001
Distal 5.16 ± 0.88 3.44 ± 0.72 <0.001
Total 5.00 ± 0.83 3.50 ± 0.71 <0.001
Degree of Inflammatory Cell Infiltration Proximal 3.28 ± 0.77 3.16 ± 0.72 0.506
Distal 3.13 ± 0.66 3.06 ± 0.84 0.742
Total 3.20 ± 0.72 3.11 ± 0.78 0.480
Degree of Collagen Deposition Proximal 4.41 ± 0.67 3.34 ± 0.75 <0.001
Distal 4.44 ± 0.62 3.44 ± 0.76 <0.001
Total 4.42 ± 0.64 3.39 ± 0.75 <0.001
Note. Data are mean ± standard deviation. CS; control stent, DS; drug stent
https://doi.org/10.1371/journal.pone.0192430.t002
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milieu between the proximal and distal urethras, granulation tissue formation was uniformly
suppressed in the DS group in this study. The possible reason for the discrepancy is that EW-
7197 has a more potent antifibrotic effect than paclitaxel for overcoming the harsher environ-
ment in the distal urethra.
Fig 5. Representative microscopic images (hematoxylin and eosin staining magnification × 2 [A,B] and Masson’s
trichrome staining magnification × 5 [C,D]) of histological sections at 8 weeks after stent placement. The thickness of
papillary projection (arrows) was significantly increased in the CS group (A) compared to the DS group (B).
Arrowhead = stent struts (A,B). The degree of collagen deposition (arrowheads) was significantly greater in the CS
group (C) than the DS group (D). The number of epithelial layers (arrows) in the CS group (C) was significantly higher
than the DS group (D). CS: control stent, DS: drug stent.
https://doi.org/10.1371/journal.pone.0192430.g005
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On histological examination, the mean thicknesses of papillary projection, thickness of sub-
mucosal fibrosis, number of epithelial layers, and degree of collagen deposition were signifi-
cantly less in the DS group than in the CS group, whereas inflammatory cell infiltration was
not different. Given the key role of TGF-β in fibrosis after stent-induced mechanical injury, a
previous study demonstrated that oral administration of EW-7197 after bare metallic stent
placement successfully inhibited granulation tissue formation by blocking the TGF-β signaling
pathway in a rat esophageal model [15]. Although inflammatory cells may be continuously
recruited by an indwelling stent acting as the stimulus, EW-7197 appears to prohibit the
inflammatory phase from progressing to the proliferative phase [10]. In a study by Kim et al.,
they placed bare metallic stents into rat urethra and investigated the efficacy of intraperitoneal
administration of IN-1233, another TGF-β type-1 receptor kinase inhibitor [27]. Their out-
comes were consistent with the present study, except for inflammatory cell infiltration, which
was significantly increased in the drug group in their study. EW-7197 was a newer TGF-β
type-1 receptor kinase inhibitor class drug and did not seem to stimulate inflammatory cell
infiltration that had been seen in IN-1233. As the accumulation of inflammatory cells may
increase the likelihood of subsequent granulation tissue formation, EW-7197 is assumed to be
a better candidate for drug-eluting stents.
Nanofiber coating by means of electrospinning was attempted to overcome the initial burst
of the drug-eluting stents that was observed with PU-covered stents [20,22,28]. Surprisingly,
the in vitro release study demonstrated that approximately 80% of the drug was eluted from
the stents within 1 day after which the elution rate slowed down and reached a plateau after 10
days. This was in marked contrast to the sustained drug delivery from the NFCS in a previous
report [17]. Despite the unexpected in vitro findings, our current EW-7197-eluting NFCS is
able to suppress granulation tissue formation after stent placement. We have two theories for
the substantial release of the drug at an early phase. As the in vitro pharmacokinetic properties
of EW-7197 may differ significantly from those in in vivo settings, including the low pH of the
canine urethra, there is a possibility that the excellent outcome resulted from a slower but
steadier in vivo release of the drug. This hypothesis warrants further studies to see if the similar
drug elution pattern can be acquired in the in vivo environment. The other assumption is that
the anti-fibrogenic effect of EW-7197 was so potent that granulation tissue formation was sup-
pressed in a prolonged fashion even with the initial burst of about 80% of EW-7197. This
encourages more research on whether EW-7197 is effective in inhibiting fibrosis with 1 or 2
days of administration rather than sustained drug release.
On RGU, filling defects and luminal irregularities due to granulation tissue formation were
seen at both ends of the stent as well as the stented urethra. This was likely attributable to the
partial degradation of the covering membrane. The acidic environment of the urethra might
have taken its toll on the PDLLA-PU complex covering membrane itself and led to the partial
degradation. As the covering membrane hinders the granulation tissue from growing through
the stent mesh, further studies are needed to develop a better EW-7197-eluting covering mate-
rial that does not degrade.
There were some limitations in this study. First, although many of the variables of interest
reached statistical significance, the sample size was too small to perform a robust statistical
analysis. However, the differences in RGU and histological findings between the two groups
were indisputable. Second, quantitative analyses for the expression levels of TGF-β and its
mediators, such as Smad2/3, were not possible because the stents were placed in a canine
urethra model. Third, we could not conduct in vivo pharmacokinetic studies on the EW-
7197-eluting NFCS because of the small sample size and also did not evaluate in vitro degrada-
tion and mechanical properties of the PDLLA fibrous membranes. Given the unexpected in
vitro drug release profile, in vivo pharmacokinetic studies are warranted. Third, some of the
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measurements in this study were obtained subjectively and quantitative data such as morpho-
metric analyses or cell counting would have provided more reliable data. Finally, long-term
effectiveness of the EW-7197-eluting NFCS was not evaluated. If granulation tissue had devel-
oped after 100% of the encapsulated EW-7197 had been released, it would have provided fur-
ther evidence supporting the effectiveness of EW-7197 in inhibiting stent-induced granulation
tissue formation.
In conclusion, the direct and local therapy with EW-7197 via a covered stent is effective and
safe for suppressing granulation tissue formation after stent placement in a canine urethral
model. The promising results in this study warrant further studies on this drug for broader
applications for stents in other parts of the organs.
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